Loading...
•
Mar 31, 2021
Mersana Q1 2021 Earnings Report
Mersana Therapeutics reported financial results for the first quarter ended March 31, 2021 and provided a business update.
Key Takeaways
Mersana Therapeutics announced the initiation of UPLIFT, a single-arm registrational strategy for evaluating UpRi in platinum-resistant ovarian cancer. The company ended the first quarter of 2021 with $228.4 million in cash and cash equivalents.
Initiated UPLIFT single-arm registration strategy for evaluation of UpRi in platinum-resistant ovarian cancer.
UpRi has demonstrated promising activity and a differentiated tolerability profile.
Remain on track to initiate the UPGRADE umbrella combination study in the third quarter of 2021.
Ended first quarter of 2021 with $228.4 million in cash.
Mersana
Mersana
Forward Guidance
The Company expects that its available funds will be sufficient to support its operating plan commitments for approximately two years.